Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans

Pharmaceutical Research

Volumn 24, Issue 2, 2007, Pages 239-247

  Kivistö, Kari T ^a   Niemi, Mikko ^b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Drug disposition; OATP; Pravastatin; Transporter; Vectorial transport

Indexed keywords

BILE SALT; CHOLESTEROL; CYTOCHROME P450; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORT PROTEIN 2B1; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 3; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1; PRAVASTATIN; PROTEIN DERIVATIVE; ROSUVASTATIN; STATIN; UNCLASSIFIED DRUG;

ABCC2 GENE; BILIARY EXCRETION; BIOTRANSFORMATION; BREAST CANCER; CHROMOSOME VARIANT; CLINICAL TRIAL; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG TOLERABILITY; DRUG TRANSPORT; ETHNIC GROUP; ETHNICITY; GENE; HAPLOTYPE; HUMAN; LIVER; MYOPATHY; NONHUMAN; POPULATION; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1B1 GENE;

ANIMALS; CARRIER PROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ORGANIC ANION TRANSPORTERS; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC; PRAVASTATIN;

EID: 33846034416     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9159-2     Document Type: Review

References (87)

1. S. M. Singhvi, H. Y. Pan, R. A. Morrison, and D. A. Willard. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br. J. Clin. Pharmacol. 29:239-243 (1990).
2. T. Hatanaka. Clinical pharmacokinetics of pravastatin. Mechanisms of pharmacokinetic events. Clin. Pharmacokinet. 39:397-412 (2000).
3. B. A. Hamelin and J. Turgeon. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci. 19:26-37 (1998).
4. D. W. Everett, T. J. Chando, G. C. Didonato, S. M. Singhvi, H. Y. Pan, and S. H. Weinstein. Biotransformation of pravastatin sodium in humans. Drug Metab. Dispos. 19:740-748 (1991).
5. J. Triscari, D. O'Donnell, M. Zinny, and H. Y. Pan. Gastrointestinal absorption of pravastatin in healthy subjects. J. Clin. Pharmacol. 35:142-144 (1995).
6. D. Williams and J. Feely. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet. 41:343-370 (2002).
7. C. Transon, T. Leemann, and P. Dayer. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur. J. Clin. Pharmacol. 50:209-215 (1996).
8. W. Jacobsen, G. Kirchner, K. Hallensleben, L. Mancinelli, M. Deters, I. Hackbarth, L. Z. Benet, K. F. Sewing, and U. Christians. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab. Dispos. 27:173-179 (1999).
9. W. Jacobsen, G. Kirchner, K. Hallensleben, L. Mancinelli, M. Deters, I. Hackbarth, K. Baner, L. Z. Benet, K. F. Sewing, and U. Christians. Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin. J. Pharmacol. Exp. Ther. 291:131-139 (1999).
10. P. J. Neuvonen, T. Kantola, and K. T. Kivistö. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther. 63:332-341 (1998).
11. T. Kantola, J. T. Backman, M. Niemi, K. T. Kivistö, and P. J. Neuvonen. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur. J. Clin. Pharmacol. 56:225-229 (2000).
12. B. Hsiang, Y. Zhu, Z. Wang, Y. Wu, V. Sasseville, W. P. Yang, and T. G. Kirchgessner. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor trans-porters. J. Biol. Chem. 274:37161-37168 (1999).
13. D. Nakai, R. Nakagomi, Y. Furuta, T. Tokui, T. Abe, T. Ikeda, and K. Nishimura. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J. Pharmacol. Exp. Ther. 297:861-867 (2001).
14. Y. Kameyama, K. Yamashita, K. Kobayashi, M. Hosokawa, and K. Chiba. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics 15:513-522 (2005).
15. M. Yamazaki, S. Akiyama, K. Ni'Inuma, R. Nishigaki, and Y. Sugiyama. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter (cMOAT). Drug Metab. Dispos. 25:1123-1129 (1997).
16. H. Fujino, D. Nakai, R. Nakagomi, M. Saito, T. Tokui, and J. Kojima. Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase. Arzneimittelforschung 54:382-388 (2004).
17. M. Hirano, K. Maeda, Y. Shitara, and Y. Sugiyama. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther. 311:139-146 (2004).
18. R. B. Kim. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about? Clin. Pharmacol. Ther. 75:381-385 (2004).
19. S. G. Simonson, A. Raza, P. D. Martin, P. D. Mitchell, J. A. Jarcho, C. D. Brown, A. S. Windass, and D. W. Schneck. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin. Pharmacol. Ther. 76:167-177 (2004).
20. R. H. Ho and R. B. Kim. Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. 78:260-277 (2005).
21. R. G. Tirona. Ethnic differences in statin disposition. Clin. Pharmacol. Ther. 78:311-316 (2005).
22. J. König, Y. Cui, A. T. Nies, and D. Keppler. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am. J. Physiol.: Gastrointest. Liver Physiol. 278:G156-G164 (2000).
23. P. Chandra and K. L. Brouwer. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm. Res. 21:719-735 (2004).
24. K. Ito, H. Suzuki, T. Horie, and Y. Sugiyama. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm. Res. 22:1559-1577 (2005).
25. J. König, A. T. Nies, Y. Cui, I. Leier, and D. Keppler. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta 1461:377-394 (1999).
26. P. M. Gerk and M. Vore. Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition. J. Pharmacol. Exp. Ther. 302:407-415 (2002).
27. D. Kobayashi, T. Nozawa, K. Imai, J. I. Nezu, A. Tsuji, and I. Tamai. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J. Pharmacol. Exp. Ther. 306:703-708 (2003).
28. M. Takeda, R. Noshiro, M. L. Onozato, A. Tojo, H. Hasannejad, X. L. Huang, S. Narikawa, and H. Endou. Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors. Eur. J. Pharmacol. 483:133-138 (2004).
29. M. Hirano, K. Maeda, H. Hayashi, H. Kusuhara, and Y. Sugiyama. Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J. Pharmacol. Exp. Ther. 314:876-882 (2005).
30. M. Hirano, K. Maeda, S. Matsushima, Y. Nozaki, H. Kusuhara, and Y. Sugiyama. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol. Pharmacol. 68:800-807 (2005).
31. T. Gerloff, B. Stieger, B. Hagenbuch, J. Madon, L. Landmann, J. Roth, A. F. Hofmann, and P. J. Meier. The sister of Pglycoprotein represents the canalicular bile salt export pump of mammalian liver. J. Biol. Chem. 273:10046-10050 (1998).
32. M. Maliepaard, G. L. Scheffer, I. F. Faneyte, M. A. van Gastelen, A. C. Pijnenborg, A. H. Schinkel, M. J. van De Vijver, R. J. Scheper, and J. H. Schellens. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61:3458-3464 (2001).
33. K. Bogman, A.K. Peyer, M. Torok, E. Kusters, and J. Drewe. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br. J. Pharmacol. 132:1183-1192 (2001).
34. E. Wang, C. N. Casciano, R. P. Clement, and W. W. Johnson. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm. Res. 18:800-806 (2001).
35. C. Chen, R. J. Mireles, S. D. Campbell, J. Lin, J. B. Mills, J. J. Xu, and T. A. Smolarek. Differential interaction of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab. Dispos. 33:537-546 (2005).
36. S. Matsushima, K. Maeda, C. Kondo, M. Hirano, M. Sasaki, H. Suzuki, and Y. Sugiyama. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J. Pharmacol. Exp. Ther. 314:1059-1067 (2005).
37. Y. Shitara, T. Itoh, H. Sato, A. P. Li, and Y. Sugiyama. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J. Pharmacol. Exp. Ther. 304:610-616 (2003).
38. W. Mück, I. Mai, L. Fritsche, K. Ochmann, G. Rohde, S. Unger, A. Johne, S. Bauer, K. Budde, I. Roots, H. H. Neumayer, and J. Kuhlmann. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin. Pharmacol. Ther. 65:251-261 (1999).
39. M. Hedman, P. J. Neuvonen, M. Neuvonen, C. Holmberg, and M. Antikainen. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin. Pharmacol. Ther. 75:101-109 (2004).
40. M. Hermann, A. Åsberg, H. Christensen, H. Holdaas, A. Hartmann, and J. L. Reubsaet. Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients. Clin. Pharmacol. Ther. 76:388-391 (2004).
41. I. Tamai and A. R. Safa. Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells. J. Biol. Chem. 265:16509-16513 (1990).
42. Z. S. Chen, T. Kawabe, M. Ono, S. Aoki, T. Sumizawa, T. Furukawa, T. Uchiumi, M. Wada, M. Kuwano, and S. I. Akiyama. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol. Pharmacol. 56:1219-1228 (1999).
43. M. Yamazaki, S. Akiyama, R. Nishigaki, and Y. Sugiyama. Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats. Pharm. Res. 13:1559-1564 (1996).
44. R. H. Ho, R. G. Tirona, B. F. Leake, H. Glaeser, W. Lee, C. J. Lemke, Y. Wang, and R. B. Kim. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130:1793-1806 (2006).
45. Y. Nishizato, I. Ieiri, H. Suzuki, M. Kimura, K. Kawabata, T. Hirota, H. Takane, S. Irie, H. Kusuhara, Y. Urasaki, A. Urae, S. Higuchi, K. Otsubo, and Y. Sugiyama. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 73:554-565 (2003).
46. J. Mwinyi, A. Johne, S. Bauer, I. Roots, and T. Gerloff. Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther. 75:415-421 (2004).
47. M. Niemi, E. Schaeffeler, T. Lang, M. F. Fromm, M. Neuvonen, C. Kyrklund, J. T. Backman, R. Kerb, M. Schwab, P. J. Neuvonen, M. Eichelbaum, and K. T. Kivistö. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14:429-440 (2004).
48. M. Niemi, P. J. Neuvonen, U. Hofmann, J. T. Backman, M. Schwab, D. Lütjohann, K. von Bergmann, M. Eichelbaum, and K. T. Kivistö. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet. Genomics 15:303-309 (2005).
49. M. K. Pasanen, J. T. Backman, P. J. Neuvonen, and M. Niemi. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 (SLCO1B1) gene in a Finnish population. Eur. J. Clin. Pharmacol. 62:409-415 (2006).
50. J. Y. Chung, J.Y. Cho, K. S. Yu, J. R. Kim, D. S. Oh, H. R. Jung, K. S. Lim, K. H. Moon, S. G. Shin, and I. J. Jang. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther. 78:342-350 (2005).
51. E. Lee, S. Ryan, B. Birmingham, J. Zalikowski, R. March, H. Ambrose, R. Moore, C. Lee, Y. Chen, and D. Schneck. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther. 78:330-341 (2005).
52. R. G. Tirona, B. F. Leake, G. Merino, and R. B. Kim. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European-and African-Americans. J. Biol. Chem. 276:35669-35675 (2001).
53. R. G. Tirona, B. F. Leake, A. W. Wolkoff, and R. B. Kim. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J. Pharmacol. Exp. Ther. 304:223-228 (2003).
54. T. Nozawa, H. Minami, S. Sugiura, A. Tsuji, and I. Tamai. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of rinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab. Dispos. 33:434-439 (2005).
55. M. Niemi, J. T. Backman, L. I. Kajosaari, J. B. Leathart, M. Neuvonen, A. K. Daly, M. Eichelbaum, K. T. Kivistö, and P. J. Neuvonen. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther. 77:468-478 (2005).
56. T. Nozawa, M. Nakajima, I. Tamai, K. Noda, J. I. Nezu, Y. Sai, A. Tsuji, and T. Yokoi. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther. 302:804-813 (2002).
57. C. Michalski, Y. Cui, T. Nies, K. Nuessler, P. Neuhaus, U. M. Zanger, K. Klein, M. Eichelbaum, D. Keppler, and J. König. A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J. Biol. Chem. 277:43058-43063 (2002).
58. M. Iwai, H. Suzuki, I. Ieiri, K. Otsubo, and Y. Sugiyama. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 14:749-757 (2004).
59. K. Maeda, I. Ieiri, K. Yasuda, A. Fujino, H. Fujiwara, K. Otsubo, M. Hirano, T. Watanabe, Y. Kitamura, H. Kusuhara, and Y. Sugiyama. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin. Pharmacol. Ther. 79:427-439 (2006).
60. M. Igel, K. A. Arnold, M. Niemi, U. Hofmann, M. Schwab, D. Lütjohann, K. von Bergmann, M. Eichelbaum, and K. T. Kivistö. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin. Pharmacol. Ther. 79:419-426 (2006).
61. M. Sasaki, H. Suzuki, K. Ito, T. Abe, and Y. Sugiyama. Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J. Biol. Chem. 277:6497-6503 (2002).
62. S. Toh, M. Wada, T. Uchiumi, A. Inokuchi, Y. Makino, Y. Horie, Y. Adachi, S. Sakisaka, and M. Kuwano. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am. J. Hum. Genet. 64:739-746 (1999).
63. K. T. Kivistö, O. Grisk, U. Hofmann, K. Meissner, K. U. Möritz, C. Ritter, A. Arnold, D. Lütjohann, K. von Bergmann, I. Klöting, M. Eichelbaum, and H. K. Kroemer. Disposition of oral and intravenous pravastatin in Mrp2-deficient TR- rats. Drug Metab. Dispos. 33:1593-1596 (2005).
64. M. Niemi, K. A. Arnold, J. T. Backman, M. K. Pasanen, U. Gödtel-Armbrust, L. Wojnowski, U. M. Zanger, P. J. Neuvonen, M. Eichelbaum, K. T. Kivistö, and T. Lang. Association of genetic polymorphism in ABCC2 with hepatic MRP2 expression and pravastatin pharmacokinetics. Pharmacogenet. Genomics (2006) (in press).
65. C. Marzolini, E. Paus, T. Buclin, and R. B. Kim. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75:13-33 (2004).
66. W. Zhang, B. N. Yu, Y. J. He, L. Fan, Q. Li, Z. Q. Liu, A. Wang, Y. L. Liu, Z. R. Tan, Fen-Jiang, Y. F. Huang, and H. H. Zhou. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 373:99-103 (2006).
67. K. Kajinami, N. Takekoshi, M. E. Brousseau, and E. J. Schaefer. Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis 177:219-234 (2004).
68. A. H. Maitland-van der Zee and E. Boerwinkle. Pharmacogenetics of response to statins: where do we stand? Curr. Atheroscler. Rep. 7:204-208 (2005).
69. I. Zineh. HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice. Future Cardiol. 1:191-206 (2005).
70. F. Pazzucconi, F. Dorigotti, G. Gianfranceschi, G. Campagnoli, M. Sirtori, G. Franceschini, and C. R. Sirtori. Therapy with HMG CoA reductase inhibitors: characteristics of the long term permanence of hypocholesterolemic activity. Atherosclerosis 117:189-198 (1995).
71. D. I. Chasman, D. Posada, L. Subrahmanyan, N. R. Cook, V. P. Stanton Jr, and P. M. Ridker. Pharmacogenetic study of statin therapy and cholesterol reduction. J. Am. Assoc. Med. 291:2821-2827 (2004).
72. F. Thompson, M. Man, K. J. Johnson, L. S. Wood, M. E. Lira, D. B. Lloyd, P. Banerjee, P. M. Milos, S. P. Myrand, J. Paulauskis, M. A. Milad, and W. J. Sasiela. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 5:352-358 (2005).
73. R. H. Knopp. Drug treatment of lipid disorders. N. Engl. J. Med. 341:498-511 (1999).
74. J. A. Tobert. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug Discov. 2:517-526 (2003).
75. P. H. Jones, J. A. Farmer, M. D. Cressman, J. M. McKenney, J. T. Wright, J. D. Proctor, D. M. Berkson, D. J. Farnham, P. M. Wolfson, and H. T. Colfer. Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study. Clin. Cardiol. 14:146-151 (1991).
76. D. R. Illingworth, D. W. Erkelens, U. Keller, G. R. Thompson, and M. J. Tikkanen. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin. Lancet 343:1554-1555 (1994).
77. S. Marshall, P. A. Meredith, and H. L. Elliott. Efficacy of low-density-lipoprotein lowering with statins. Lancet 344:684 (1994).
78. E. Reihner, M. Rudling, D. Stahlberg, L. Berglund, S. Ewerth, I. Björkhem, K. Einarsson, and B. Angelin. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N. Engl. J. Med. 323:224-228 (1990).
79. D. D. Cilla Jr, L. R. Whitfield, D. M. Gibson, A. J. Sedman, and E. L. Posvar. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin. Pharmacol. Ther. 60:687-695 (1996).
80. T. A. Miettinen, H. Gylling, N. Lindbohm, T. E. Miettinen, R. A. Rajaratnam, and H. Relas. Finnish Treat-to-Target Study Investigators. Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J. Lab. Clin. Med. 141:131-137 (2003).
81. R. Tachibana-Iimori, Y. Tabara, H. Kusuhara, K. Kohara, R. Kawamoto, J. Nakura, K. Tokunaga, I. Kondo, Y. Sugiyama, and T. Miki. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab. Pharmacokinet. 19:375-380 (2004).
82. M. A. Pfeffer, A. Keech, F. M. Sacks, S. M. Cobbe, A. Tonkin, R. P. Byington, B. R. Davis, C. P. Friedman, and E. Braunwald. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 105:2341-2346 (2002).
83. P. D. Thompson, P. Clarkson, and R. H. Karas. Statin-associated myopathy. J. Am. Assoc. Med. 289:1681-1690 (2003).
84. K. Morimoto, T. Oishi, S. Ueda, M. Ueda, M. Hosokawa, and K. Chiba. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metab. Pharmacokinet. 19:453-455 (2004).
85. I. Björkhem, T. Miettinen, E. Reihner, S. Ewerth, B. Angelin, and K. Einarsson. Correlation between serum levels of some cholesterol precursors and activity of HMG-CoA reductase in human liver. J. Lipid Res. 28:1137-1143 (1987).
86. H. J. Kempen, J. F. Glatz, J. A. Gevers Leuven, H. A. van der Voort, and M. B. Katan. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J. Lipid Res. 29:1149-1155 (1988).
87. T. A. Miettinen, R. S. Tilvis, and Y. A. Kesäniemi. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am. J. Epidemiol. 131:20-31 (1990).